Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 2,452 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ABI-007(Abraxane) Clear all
Recruiting Phase 3 Interventional

A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)

NCT07743164
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
R-DXd, Bevacizumab, Carboplatin, Paclitaxel, Gemcitabine, Pegylated liposomal doxorubicin (PLD)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Fountain Valley, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 9:41 AM EDT
Completed Phase 1 Interventional

Combination Paclitaxel, Carboplatin and Temozolomide

NCT00249964
View directory record Official record
Conditions
Lung Diseases, Cancer
Interventions
Combination Treatment - Cohort 1, Combination Treatment - Cohort 2, Combination Treatment - Cohort 3, Combination Treatment - Cohort 4
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 28, 2026, 9:41 AM EDT
Active, not recruiting Phase 2 Interventional

Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis

NCT04858009
View directory record Official record
Conditions
Metastatic Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v8, Metastatic Malignant Neoplasm in the Peritoneum
Interventions
Cisplatin, Hyperthermic Intraperitoneal Chemotherapy, Nab-paclitaxel, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 9:41 AM EDT
Completed Phase 2 Interventional

Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer

NCT00002632
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
paclitaxel
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
28
States / cities
Palo Alto, California • Stanford, California • Tampa, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 28, 2026, 9:41 AM EDT
Completed Phase 2Phase 3 Interventional

Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer

NCT00006229
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, rebimastat
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
18 Years to 120 Years
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 28, 2026, 9:41 AM EDT
Completed Phase 2 Interventional

Phase II CT-2103/Carboplatin in Ovarian Cancer

NCT00069901
View directory record Official record
Conditions
Ovarian Neoplasm
Interventions
CT-2103 (poly(L)glutamate-paclitaxel), carboplatin
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years and older · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
17
States / cities
Greenbrae, California • Stockton, California • South Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2008 · Synced Oct 28, 2026, 9:41 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers

NCT07769502
View directory record Official record
Conditions
Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma
Interventions
Telisotuzumab Adizutecan, Gemcitabine, Nab-Paclitaxel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Hattiesburg, Mississippi
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 9:41 AM EDT
Terminated Phase 2 Interventional Results available

Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

NCT01207102
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Abraxane, Carboplatin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 15, 2014 · Synced Oct 28, 2026, 9:41 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer

NCT00536939
View directory record Official record
Conditions
Breast Cancer
Interventions
Enzastaurin, Bevacizumab, Paclitaxel, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Newark, Delaware • Galesburg, Illinois • Fort Wayne, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 28, 2026, 9:41 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT00003944
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, paclitaxel, topotecan hydrochloride, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 28, 2026, 9:41 AM EDT
Terminated Phase 2 Interventional

Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

NCT05420636
View directory record Official record
Conditions
Small-cell Lung Cancer, Neuroendocrine Carcinoma
Interventions
Iadademstat, Paclitaxel
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Buffalo, New York • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 28, 2026, 9:41 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer

NCT06016270
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
hSTC810 400 mg + Paclitaxel, hSTC810 800 mg + Paclitaxel
Drug
Lead sponsor
STCube, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 28, 2026, 9:41 AM EDT
Completed Phase 1 Interventional

Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors

NCT00572078
View directory record Official record
Conditions
SOLID TUMORS
Interventions
Sorafenib
Drug
Lead sponsor
Safi Shahda
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 28, 2026, 9:41 AM EDT
Completed Phase 3 Interventional

S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

NCT00003120
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2012
U.S. locations
93
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Oct 28, 2026, 9:41 AM EDT
Recruiting Phase 2 Interventional

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

NCT01042379
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
Interventions
Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 28, 2026, 9:41 AM EDT
Completed Phase 1 Interventional

Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors

NCT01653470
View directory record Official record
Conditions
Cancer
Interventions
Paclitaxel, 5-Fluorouracil (5FU), Carboplatin, Leucovorin, Irinotecan, BMS-906024
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 28, 2026, 9:41 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00287989
View directory record Official record
Conditions
Lung Cancer
Interventions
Carboplatin, erlotinib hydrochloride, Paclitaxel
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 28, 2026, 9:41 AM EDT
Terminated Phase 3 Interventional

Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

NCT00054197
View directory record Official record
Conditions
Lung Cancer
Interventions
gemcitabine hydrochloride, paclitaxel poliglumex, vinorelbine tartrate
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
10
States / cities
Birmingham, Alabama • Gilroy, California • Coral Springs, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 28, 2026, 9:41 AM EDT
Completed Phase 1 Interventional

Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

NCT03430882
View directory record Official record
Conditions
Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Interventions
Carboplatin, Paclitaxel, Sapanisertib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 28, 2026, 9:41 AM EDT
Completed Phase 2 Interventional

Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer

NCT00062179
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, celecoxib, paclitaxel, Placebo
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 28, 2026, 9:41 AM EDT
Completed Phase 1 Interventional

Chemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

NCT00033410
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, tirapazamine, radiation therapy
Drug · Radiation
Lead sponsor
California Cancer Consortium
Network
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Duarte, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Oct 28, 2026, 9:41 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Assessment of Paclitaxel-Induced Neuropathy

NCT01953159
View directory record Official record
Conditions
Cancer, Breast Cancer, Ovarian Cancer
Interventions
Blood Collection, Patient Questionnaires
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 28, 2026, 9:41 AM EDT
Terminated Phase 1Phase 2 Interventional

Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor

NCT00004159
View directory record Official record
Conditions
Lung Cancer
Interventions
gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Oct 28, 2026, 9:41 AM EDT
Completed Phase 2 Interventional

Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer

NCT01263886
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
ombrabulin (AVE8062), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Muscle Shoals, Alabama • Hot Springs, Arkansas • Anaheim, California + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 28, 2026, 9:41 AM EDT